Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ).
NeuroScientific Biopharmaceuticals Limited reported a significant decrease in income from ordinary activities, down by 93.05% to $166,078 for the year ended 30 June 2025. The company also experienced a substantial increase in losses, with a 669.23% rise in loss after tax, amounting to $1,845,513. Despite these financial challenges, the company’s financial statements received an unqualified audit opinion, indicating no significant issues were found in their financial reporting. The company did not declare any dividends for the year, and the net tangible assets per ordinary share decreased from 3.50 cents to 2.22 cents, reflecting the financial strain the company is under.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development of therapeutic products targeting neurodegenerative conditions. The company is engaged in research and development to address unmet medical needs in neuroscience.
Average Trading Volume: 636,526
Technical Sentiment Signal: Buy
Current Market Cap: A$54.87M
For a thorough assessment of NSB stock, go to TipRanks’ Stock Analysis page.